

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-2978  
WWW.FULBRIGHT.COM

TKALE@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3015

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

June 11, 2008

Brandon J. Fetterolf, Examiner  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

## CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

June 11, 2008  
Date

  
Tamara A. Kale

RE: *U.S. Patent Application No. 10/043,877 Confirmation No.: 6285*  
*Entitled "ANTIHELMINTHIC DRUGS AS A TREATMENT FOR*  
*HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhyay et al.*  
*Our reference: INRP:095US*

Dear Examiner Fetterolf:


After reviewing each of the Office Actions and the Notice of Allowability, it has come to our attention that the Supplemental Information Disclosure Statement, Form PTO-1449 and 2 references submitted on July 30, 2003, were apparently never signed off by an Examiner.

For your convenience we have attached a copy of the transmittal letter, Supplemental Information Disclosure Statement and Form PTO-1449 that were filed with the Patent and Trademark Office (PTO) on July 30, 2003. Also attached is a copy of the PTO stamped postcard indicating the documents submitted. The copies of the references previously submitted have not been attached. Please let us know if you would like us to resubmit those as well.

Please review and approve this Supplemental Information Disclosure Statement. If you need additional information, please let us know.

Thank you for your assistance in this matter.

Very truly yours,



Tamara A. Kale

TAK/jst  
Attachments


# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MDLAPAZ@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-5639

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

July 30, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
July 30, 2003	
Date	Monica A. De La Paz

MS DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/043,877 entitled "ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES" – Tapas Mukhopadhyay et al.*  
*Our reference: INRP:095US*  
*Client reference: MDA99-067*


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B4-B5).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:095US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. P-54, 662

MAD/cas  
Encl.: As noted

25319830.1

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Tapas Mukhopadhyay *et al.*

Serial No.: 10/043,877


Filed: January 9, 2002

For: ANTIHELMINTHIC DRUGS AS A  
TREATMENT FOR  
HYPERPROLIFERATIVE DISEASES

Group Art Unit: 1641

Examiner: Unknown

Atty. Dkt. No.: INRP:095US



**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS DD**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:095US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. P-54,662  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: July 30, 2003

Form PTO-1449 (modified)		Atty. Docket No. INRP:095US	Serial No. 10/043,877
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT		Applicant Tapas Mukhopadhyay <i>et al.</i>	
(Use several sheets if necessary)		Filing Date: January 9, 2002	Group: 1641
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B4	2 342 470	9-30-02	Canada			
	B5	WO 02/076454 A1	10-3-02	PCT			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25319410.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:	Priority Date:
<input type="checkbox"/> Foreign priority already claimed	
<input type="checkbox"/> Continuation <input type="checkbox"/> CIP	<input type="checkbox"/> Divisional CPA <input type="checkbox"/>
<input type="checkbox"/> Specification: Pages	<input type="checkbox"/> Drawings: Sheets
<input type="checkbox"/> Response to Office Action Dated:	<input type="checkbox"/> Final Rejection
<input checked="" type="checkbox"/> Other: SIDS; References (B4-B5); Transmittal Ltr.; Form 1449; Postcard	
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing <input type="checkbox"/> Exp. Mail:

**IDENTIFICATION OF APPLICATION**

Serial No.: 10/043,877	
Title: ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES	
Applicant: Tapas Mukhopadhyay et al.	Attorney: MAD
Client: Introgen	F&J File No.: INRP:095US
Mailed: 7-30-03	Filed: Due Date:

